ARCA biopharma, Inc. (ABIO)

NASDAQ: ABIO · IEX Real-Time Price · USD
2.09
+0.03 (1.46%)
Oct 3, 2022 3:56 PM EDT - Market closed
1.46%
Market Cap 30.12M
Revenue (ttm) n/a
Net Income (ttm) -16.81M
Shares Out 14.41M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,072
Open 2.07
Previous Close 2.06
Day's Range 2.06 - 2.10
52-Week Range 1.71 - 2.95
Beta 1.90
Analysts Buy
Price Target n/a
Earnings Date Oct 31, 2022

About ABIO

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA bio... [Read more...]

Industry Biotechnology
CEO Michael Bristow
Employees 17
Stock Exchange NASDAQ
Ticker Symbol ABIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Buy
Stock Forecasts

News

ARCA biopharma Announces Second Quarter 2022 Financial Results

WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

2 months ago - GlobeNewsWire

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors.

3 months ago - GlobeNewsWire

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor.

4 months ago - GlobeNewsWire

ARCA biopharma Announces First Quarter 2022 Financial Results

WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

5 months ago - GlobeNewsWire

ARCA biopharma Establishes Special Committee of the Board of Directors

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

5 months ago - GlobeNewsWire

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor, as a potential treatment for patients hospitalized wit...

6 months ago - Benzinga

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

WESTMINSTER, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly ...

6 months ago - GlobeNewsWire

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Topline data from Phase 2b ASPEN-COVID-19 clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the last week of March 2022 Topline data from Phase 2b ASPEN-COVID-19 clin...

6 months ago - GlobeNewsWire

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

8 months ago - GlobeNewsWire

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Po...

WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiov...

10 months ago - GlobeNewsWire

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

10 months ago - GlobeNewsWire

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

11 months ago - GlobeNewsWire

ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged

The Data and Safety Monitoring Committee (DSMC) has completed a pre-specified interim analysis for ARCA biopharma Inc's (NASDAQ: ABIO) ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinan...

11 months ago - Benzinga

ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based...

WESTMINSTER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

11 months ago - GlobeNewsWire

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a ...

WESTMINSTER, Colo., Sept. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

1 year ago - GlobeNewsWire

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

1 year ago - GlobeNewsWire

ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

1 year ago - GlobeNewsWire

ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment f...

WESTMINSTER, Colo., July 13, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

1 year ago - GlobeNewsWire

ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th

WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies...

1 year ago - GlobeNewsWire

ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

1 year ago - GlobeNewsWire

Christopher Graybill Joins ARCA as Vice President, Clinical Development

WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

1 year ago - GlobeNewsWire

ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer

WESTMINSTER, Colo., May 03, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies ...

1 year ago - GlobeNewsWire

ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., March 18, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapie...

1 year ago - GlobeNewsWire

3 Net-Net Working Capital Stocks

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...

Other symbols: ATHAMTCR
1 year ago - GuruFocus

ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00...

1 year ago - GlobeNewsWire